Ultrasonography, computed tomography and magnetic resonance imaging of hepatocellular carcinoma: Toward improved treatment decisions

Oncology

Volumn 81, Issue SUPPL. 1, 2011, Pages 86-99

  Murakami, Takamichi ^a   Imai, Yasuharu ^b   Okada, Masahiro ^a   Hyodo, Tomoko ^a   Lee, Won Jae ^d   Kim, Myeong Jin ^e   Kim, Tonsok ^c   Choi, Byung Ihn ^f  

^a KINKI UNIVERSITY   (Japan)

^b Ikeda Municipal Hospital   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Samsung Medical Center   (South Korea)

^e Yonsei University   (South Korea)

^f Seoul National University College of Medicine   (South Korea)

Author keywords

Computed tomography; Contrast media; Dysplastic nodule; Hepatocellular carcinoma; Liver neoplasms; Magnetic resonance imaging; Microbubbles; Ultrasound

Indexed keywords

CONTRAST MEDIUM; GADOXETIC ACID; IODINE; PERFLUBUTANE; SORAFENIB; SUPERPARAMAGNETIC IRON OXIDE; WATER;

CANCER THERAPY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTRAST ENHANCEMENT; DECISION MAKING; DENSITY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FOURIER TRANSFORM INFRARED PHOTOACOUSTIC SPECTROSCOPY; HEMODYNAMICS; IMAGE QUALITY; LIVER ARTERIOGRAPHY; LIVER CELL CARCINOMA; LIVER NODULE; LIVER PARENCHYMA; LIVER PERFUSION; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; SIGNAL NOISE RATIO; THREE DIMENSIONAL IMAGING; TISSUE BLOOD FLOW; TISSUE PERFUSION;

ANGIOGRAPHY; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MICROBUBBLES; MULTIDETECTOR COMPUTED TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84855338579     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000333267     Document Type: Review

References (54)

1. Kim TK, Lee KH, Khalili K, Jang HJ: Hepatocellular nodules in liver cirrhosis: contrast- enhanced ultrasound. Abdom Imaging 2011; 36: 244-263.
2. Murakami T, Onishi H, Mikami K, et al.: Determining the optimal timing for early arterial phase hepatic CT imaging by measuring abdominal aortic enhancement in variable contrast injection protocols. J Comput Assist Tomogr 2006; 30: 206-211. (Pubitemid 43739297)
3. Takahashi S, Murakami T, Takamura M, et al.: Multi-detector row helical CT angiography of hepatic vessels: depiction with dual-arterial phase acquisition during single breath hold. Radiology 2002; 222: 81-88. (Pubitemid 34031470)
4. Hashimoto K, Murakami T, Dono K, et al.: Quantitative tissue blood flow measurement of the liver parenchyma: comparison between xenon CT and perfusion CT. Dig Dis Sci 2007; 52: 943-949. (Pubitemid 46481247)
5. Noguchi Y, Murakami T, Kim T, Hori M, Osu ga K, Kawata S, Kumano S, Okada A, Sugiura T, Nakamura H: Detection of hepatocellular carcinoma: comparison of dynamic MR imaging with dynamic double arterial phase helical CT. AJR Am J Roentgenol 2003; 180: 455-460. (Pubitemid 36135031)
6. Imai Y, Murakami T, Yoshida S, et al.: Superparamagnetic iron oxide-enhanced MR images of hepatocellular carcinoma: correlation with histological grading. Hepatology 2000; 32: 205-212. (Pubitemid 30614651)
7. Saito K, Kotake F, Ito N, et al.: Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005; 4: 1-9.
8. Tsuda N, Okada M, Murakami T: Potential of gadolinium-ethoxybenzyl- diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 2007; 42: 242-247. (Pubitemid 46398863)
9. Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, Fukuda K, Igura T, Sawai Y, Morimoto O, Hori M, Nagano H, Wakasa K, Hayashi N, Murakami T: Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010; 20: 2405-2413.
10. Okada M, Imai Y, Kim T, Kogita S, Takamura M, Kumano S, Onishi H, Hori M, Fukuda K, Hayashi N, Wakasa K, Sakamoto M, Murakami T: Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran- enhanced magnetic resonance imaging. J Magn Reson Imaging 2010; 32: 903-913.
11. Kagawa Y, Okada M, Kumano S, Katsube T, Imaoka I, Tanigawa N, Kudo M, Ishii K, Murakami T: Optimal scanning protocol of arterial dominant phase for hypervascular hepatocellular carcinoma with gadolinium-ethoxybenzyl- diethylenetriamine pentaacetic acid-enhanced MR. J Magn Reson Imaging 2011; 33: 864-872.
12. Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
13. Burns PN, Wilson SR: Microbubble contrast for radiological imaging. 1. Principles. Ultrasound Q 2006; 22: 5-13.
14. Brannigan M, Burns PN, Wilson SR: Blood flow patterns in focal liver lesions at microbubble- enhanced US. Radiographics 2004; 24: 921-935. (Pubitemid 38943326)
15. Matsui O, Kadoya M, Kameyama T, et al.: Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991; 178: 493-497.
16. Hayashi M, Matsui O, Ueda K, et al.: Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR 1999; 172: 969-976. (Pubitemid 29505622)
17. Jang HJ, Kim TK, Burns PN, Wilson SR: Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology 2007; 244: 898-906. (Pubitemid 47292103)
18. Bhayana D, Kim TK, Jang HJ, Burns PN, Wilson SR: Hypervascular liver masses on contrast-enhanced ultrasound: the importance of washout. AJR 2010; 194: 977-983.
19. Moriyasu F, Itoh K: Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol 2009; 193: 86-95.
20. Luo W, Numata K, Morimoto M, et al.: Focal liver tumors: characterization with 3D perflubutane microbubble contrast agent-enhanced US versus 3D contrast-enhanced multidetector CT. Radiology 2009; 251: 287-295.
21. Kudo M, Hatanaka K, Kumada T, et al.: Double- contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma. Am J Gastroenterol 2011; 106: 368-370.
22. Luo W, Numata K, Morimoto M, et al.: Role of Sonazoid-enhanced three-dimensional ultrasonography in the evaluation of percutaneous radiofrequency ablation of hepatocellular carcinoma. Eur J Radiol 2010; 75: 91-97.
23. Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H: Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol 2007; 33: 318-325. (Pubitemid 46240604)
24. Minami Y, Chung H, Kudo M, et al.: Radiofrequency ablation of hepatocellular carcinoma: value of virtual CT sonography with magnetic navigation. AJR Am J Roentgenol 2008; 190:W335-W341.
25. Cuenod C, Leconte I, Siauve N, et al.: Early changes in liver perfusion caused by occult metastases in rats: detection with quantitative CT. Radiology 2001; 218: 556-561.
26. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY: Dynamic CT measurement of cerebral blood flow: a validation study. AJNR Am J Neuroradiol 1999; 20: 63-73. (Pubitemid 30417673)
27. Willett CG, Boucher Y, di Tomaso E, et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147. (Pubitemid 38524883)
28. Ma SH, Le HB, Jia BH, et al.: Peripheral pulmonary nodules: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer 2008; 8: 186.
29. Ippolito D, Sironi S, Pozzi M, et al.: Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization. Acad Radiol 2008; 15: 919-927. (Pubitemid 352033551)
30. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
31. Okada M, Kim T, Murakami T: Hepatocellular nodules in liver cirrhosis: state of the art CT evaluation (perfusion CT/volume helical shuttle scan/dual-energy CT, etc.). Abdom Imaging 2011; 36: 273-281.
32. Bader TR, Herneth AM, Blaicher W, et al.: Hepatic perfusion after liver transplantation: noninvasive measurement with dynamic single-section CT. Radiology 1998; 209: 129-134. (Pubitemid 28464658)
33. Hashimoto K, Murakami T, Dono K, et al.: Assessment of the severity of liver disease and fibrotic change: the usefulness of hepatic CT perfusion imaging. Oncol Rep 2006; 16: 677-683.
34. Genant HK, Boyd D: Quantitative bone mineral analysis using dual energy computed tomography. Invest Radiol 1977; 12: 545-551. (Pubitemid 8258543)
35. Brooks RA: A quantitative theory of the Hounsfield unit and its application to dual energy scanning. J Comput Assist Tomogr 1977; 1: 487-493.
36. Nakayama Y, Awai K, Funama Y, et al.: Abdominal CT with low tube voltage: preliminary observations about radiation dose, contrast enhancement, image quality, and noise. Radiology 2005; 237: 945-951. (Pubitemid 41636385)
37. Yeh BM, Shepherd JA, Wang ZJ, et al.: Dual-energy and low-kVp CT in the abdomen. AJR Am J Roentgenol 2009; 193: 47-54.
38. Schindera ST, Nelson RC, Mukundan S Jr, et al.: Hypervascular liver tumors: low tube voltage, high tube current multi-detector row CT for enhanced detection - phantom study. Radiology 2008; 246: 125-132. (Pubitemid 350305035)
39. Marin D, Nelson RC, Samei E, et al.: Hypervascular liver tumors: low tube voltage, high tube current multidetector CT during later hepatic arterial phase for detection - initial clinical experience. Radiology 2009; 251: 771-779.
40. Reimer P, Rummeny EJ, Daldrup HE, et al.: Clinical results with Resovist: a phase 2 clinical trial. Radiology 1995; 195: 489-496.
41. Saini S, Stark DD, Hahn PF, et al.: Ferrite particles: a superparamagnetic MR contrast agent for enhanced detection of liver carcinoma. Radiology 1987; 162: 217-222. (Pubitemid 17001813)
42. Ferrucci JT, Stark DD: Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. AJR Am J Roentgenol 1990; 155: 943-950. (Pubitemid 20356987)
43. Yamamoto H, Yamashita Y, Yoshimatsu S, et al.: Hepatocellular carcinoma in cirrhotic livers: detection with unenhanced and iron oxide- enhanced MR imaging. Radiology 1995; 195: 106-112.
44. Hori M, Murakami T, Kim T, et al.: Detection of hypervascular hepatocellular carcinoma: comparison of SPIO-enhanced MRI with dynamic helical CT. J Comput Assist Tomogr 2002; 26: 701-710. (Pubitemid 35423371)
45. Kim YK, Kwak HS, Kim CS, Chung GH, Han YM, Lee JM: Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology 2006; 238: 531-541. (Pubitemid 43134365)
46. Imai Y, Murakami T, Hori M, et al.: Hypervascular hepatocellular carcinoma: Combined dynamic MDCT and SPIO-enhanced MRI versus combined CTHA and CTAP. Hepatol Res 2008; 38: 147-158.
47. Yukisawa S, Okugawa H, Masuya Y, et al.: Multidetector helical CT plus superparamagnetic iron oxide-enhanced MR imaging for focal hepatic lesions in cirrhotic liver: a comparison with multi-phase CT during hepatic arteriography. Eur J Radiol 2007; 61: 279-289. (Pubitemid 46096686)
48. Kim YK, Kwak HS, Han YM, et al.: Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography. J Comput Assist Tomogr 2007; 31: 702-711. (Pubitemid 47482489)
49. Hamm B, Staks T, Muhler A, et al.: Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195: 785-792.
50. Bellin MF, Vasile M, Morel-Precetti S: Currently used non-specific extracellular MR contrast media. Eur Radiol 2003; 13: 2688-2698. (Pubitemid 37527075)
51. Brasch RC: New directions in the development of MR imaging contrast media. Radiology 1992; 183: 1-11.
52. Di Martino M, Marin D, Guerrisi A, Baski M, Galati F, Rossi M, Brozzetti S, Masciangelo R, Passariello R, Catalano C: Radiology 2010; 256: 806-816.
53. Park G, Kim YK, Kim CS, Yu HC, Hwang SB: Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol 2010; 83: 1010-1016.
54. Hayashi M, Matsui O, Ueda K, et al.: Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002; 225: 143-149.